Baird analyst Jack Allen downgraded Decibel Therapeutics (DBTX) to Neutral from Outperform with a price target of $5.25, down from $21. The takeover by Regeneron (REGN) for $4.00 per share in cash and an additional $3.50 per share in contingent value rights seems likely to close on schedule, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics downgraded to Hold from Buy at JonesResearch
- Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron
- Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue